United Kingdom RNA Based Therapeutics Market Insight
The United Kingdom RNA Based Therapeutics Market is growing at an 15.82% CAGR, driven by advances in mRNA technology, rising genetic medicine investment, and demand for precision therapeutics, the market evolves with mRNA vaccines, siRNA, antisense therapies, and RNA delivery innovations improving outcomes.
United Kingdom RNA Based Therapeutics Market Insights Forecasts to 2035
- The United Kingdom RNA Based Therapeutics Market Size Was Estimated at USD 17.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 15.82% from 2025 to 2035
- The United Kingdom RNA Based Therapeutics Market Size is Expected to Reach USD 75.6 Million by 2035
Notable Insights for United Kingdom RNA Based Therapeutics Market
- By product type, mRNA therapeutics dominate with approximately 40–55% share due to vaccine and oncology pipeline expansion
- By application, infectious diseases and oncology collectively account for nearly 50–65% of total demand.
- Around 55–65% of RNA-based therapies in development focus on rare and genetic disorders.
- Hospitals and specialty treatment centers contribute nearly 50–60% of total therapy adoption.
- RNA delivery technologies such as lipid nanoparticles are witnessing 25–35% faster innovation growth compared to conventional systems.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom RNA Based Therapeutics Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom RNA Based Therapeutics Market
- Moderna Inc.
- BioNTech SE
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Pfizer Inc.
- Sanofi
- Others
Recent Developments:
- In August 2025, UK government announced a £29.6M RNA Biofoundry in Darlington to accelerate clinical-grade RNA production and fast-track therapies for cancer and other diseases
- In February 2024, UK begins first-in-human mRNA cancer vaccine trials at Hammersmith Hospital, advancing personalized oncology treatments and strengthening the national RNA therapeutics pipeline.
Market Segmentation:
United Kingdom RNA Based Therapeutics Market, By Product Type
- mRNA Therapeutics
- siRNA Therapeutics
- Antisense Oligonucleotides
- RNA Aptamers
- Others
United Kingdom RNA Based Therapeutics Market, By Application
- Infectious Diseases
- Oncology
- Rare Genetic Disorders
- Cardiovascular Diseases
- Others
United Kingdom RNA Based Therapeutics Market, By End User
- Hospitals & Specialty Clinics
- Research Institutes
- Home Care Settings
- Others
United Kingdom RNA Based Therapeutics Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK RNA-Based Therapeutics Market is poised for strong growth driven by expanding mRNA applications, increasing genetic disease research, and robust government support for advanced therapeutics. Experts emphasize that mRNA vaccines, RNA interference technologies, and innovative delivery platforms will shape the market’s future. Rising demand for precision medicine and personalized treatments is accelerating adoption across oncology and rare diseases. Continued investment in R&D, regulatory support, and collaborations between biotech firms and academic institutions will significantly influence market expansion through 2035.